|
CANCERS BRONCHIQUES A PETITES CELLULES : CHIMIOTHERAPIE
META-ANALYSES ET REVUES SYSTEMATIQUES |
|
|
Référence |
Méthodologie |
Critère de jugement |
Nombre d'essais |
Nombre de patients |
Résultat |
|
Rôle de l'étoposide et/ou du cisplatine
(CE) dans la chimiothérapie |
|||||
|
Mascaux, 2000 (1) |
MARSL |
Survie globale |
36 |
7173 |
S en faveur de l'étoposide HR
= 0,61 (IC 95 % 0,57 – 0,66) et de l'association
CE HR
= 0,57 (0,51 – 0,64) |
|
Pujol, 2000 (2) |
MAI |
Survie à 1 an |
19 |
4050 |
S en faveur du cisplatine OR
= 0,80 (0,69 – 0,93) |
|
Jiang, 2012 (3) |
MARSL |
Survie globale |
12 (ME) |
|
S en faveur cisplatine + étoposide HR = 0,87 (0,78 – 0,97) |
|
Rôle des facteurs de croissance dans la
chimiothérapie |
|||||
|
Berghmans, 2002 (4) |
MARSL |
Survie globale |
6 (entretien) |
1222 |
NS HR
= 1,004 (0,89 – 1,13) |
|
Berghmans, 2002 (4) |
|
Survie globale |
2 (accélération) |
468 |
NS HR
= 0,82 (0,67 - 1,00) |
|
Entretien/consolidation |
|||||
|
Bozcuk, 2005 (5) |
MARSL |
Survie à 1 an et 2
ans |
14 |
2550 |
S (en faveur
consolidation/entretien) OR
= 0,67 (0,56 – 0,79) et 0,67 (0,53
– 0,86) |
|
Rossi, 2010 (6) |
MARSL |
Survie globale |
22 |
3688 |
NS HR
= 0,93 (0,87 - 1,00) |
|
Chimiothérapie intensive avec greffe de
cellules souches |
|||||
|
Jiang, 2009 (7) |
MAI |
Survie globale |
5 |
641 |
NS HR
= 0,94 (0,80 - 1,10) |
|
Rôle de l'irinotécan avec cisplatine (CI
par rapport à CE) dans la chimiothérapie |
|||||
|
Jiang, 2010 (8) |
MAI |
Survie globale |
6 |
1476 |
S en faveur CI HR = 0,81 (0,66 – 0,99) |
|
Lima, 2010 (9) |
MARSL |
Survie globale |
5 |
1561 |
S en faveur CI HR = 0,84 (0,75 – 0,93) |
|
Shao, 2012 (10) |
MAI |
Survie globale |
7 |
2027 |
S en faveur CI HR = 0,81 (0,71 – 0,93) |
|
Cisplatine vs carboplatine |
|||||
|
Rossi, 2012 (11) |
MADI |
Survie globale |
4 |
663 |
NS HR =1,08 (0,92 – 1,27) |
Références
(1) Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000 Oct;30(1):23-36.
(2) Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000 Jul;83(1):8-15.
(3) Jiang L, Yang KH, Guan QL, Mi DH, Wang J. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials. Intern Med J 2012 Dec;42(12):1297-309.
(4) Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002 Aug;37(2):115-23.
(5) Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005 Dec 15;104(12):2650-7.
(6) Rossi A, Garassino MC, Cinquini M, Sburlati P, Di MM, Farina G, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010 Nov;70(2):119-28.
(7) Jiang J, Shi HZ, Deng JM, Liang QL, Qin SM, Wu C. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. Lung Cancer 2009 Aug;65(2):214-8.
(8) Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010 Jun;5(6):867-73.
(9) Lima JP, dos Santos LV, Sasse EC, Lima CS, Sasse AD. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010 Dec;5(12):1986-93.
(10) Shao N, Jin S, Zhu W. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2012 Feb;7(2):470-2.
(11) Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012 Feb 14;106(4):658-65.